Bioventus appoints Robert Claypoole as President and CEO effective Jan 10, 2024

Bioventus Inc.

Claypoole appointed President and CEO effective Jan 10, 2024, succeeding interim CEO Anthony Bihl.
Compensation: $800k base, 100% bonus target, $750k sign-on cash, 375k RSUs and 850k options.
Claypoole previously EVP at Mölnlycke Health Care, leading $1.2B wound care; also held senior roles at Medtronic and Covidien.
Company reaffirms full year financial guidance previously announced on November 7, 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert E. Claypoole

President and Chief Executive Officer

BVS · Bioventus Inc.

Effective: 2024-01-10
Filed: December 21, 2023, 6:59 PM ET

Robert E. Claypoole has been appointed as the Company’s President and Chief Executive Officer, and as a Class III director of the Company, effective January 10, 2024

Departed (interim)

Anthony P. Bihl III

Interim President and Chief Executive Officer

BVS · Bioventus Inc.

Effective: 2024-01-10
Successor: Robert E. Claypoole
Filed: December 21, 2023, 6:59 PM ET

succeeding Anthony P. Bihl III, the Company’s current Interim President and Chief Executive Officer, in such roles.

Appointed

Robert E. Claypoole

Class III Director

BVS · Bioventus Inc.

Effective: 2024-01-10
Filed: December 21, 2023, 6:59 PM ET

and as a Class III director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Claypoole was appointed as President and Chief Executive Officer at Bioventus Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Robert E. Claypoole has been appointed as the Company’s President and Chief Executive Officer, and as a Class III director of the Company, effective January 10, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony P. Bihl III departed as Interim President and Chief Executive Officer at Bioventus Inc..

Action: succeeded
Role: Interim President and Chief Executive Officer

Exact text from the filing

succeeding Anthony P. Bihl III, the Company’s current Interim President and Chief Executive Officer, in such roles.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Claypoole was appointed as Class III Director at Bioventus Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

and as a Class III director of the Company

View on SEC.gov

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-300412

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.